Comparative Pharmacology
Head-to-head clinical analysis: CALCIPOTRIENE versus ROCALTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPOTRIENE versus ROCALTROL.
CALCIPOTRIENE vs ROCALTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Calcitriol, the active form of vitamin D, binds to vitamin D receptors in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone mineralization.
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
Oral, 0.25 mcg once daily; may increase to 0.5 mcg once daily based on response. Typical adult dose is 0.25-0.5 mcg/day.
None Documented
None Documented
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
Terminal elimination half-life is approximately 25–35 hours after oral administration. Clinical context: Once-weekly or thrice-weekly dosing achieves steady state in 1–2 weeks.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Primarily biliary/fecal; approximately 50% of dose recovered in feces within 24 hours. Renal excretion accounts for <5% of unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog